Nesspor
Thomas Nesspor, Collegeville, PA US
Patent application number | Description | Published |
---|---|---|
20080299133 | Anti-Il-12 Antibody Based Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 12-04-2008 |
20100216234 | Anti-IL-12 Antibody Based Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 08-26-2010 |
Thomas Nesspor, Radnor, PA US
Patent application number | Description | Published |
---|---|---|
20090117104 | GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses - Mammalian GLP-2 mimetibodies, polypeptides and nucleic acids are disclosed. Methods of utilizing the mimetibodies and polypeptides to treat GLP-2 related diseases are also disclosed. | 05-07-2009 |
Thomas Nesspor, Spring House, PA US
Patent application number | Description | Published |
---|---|---|
20150259401 | Antibodies with Improved Half-Life in Ferrets - The antibodies, immunoglobulin constructs, or immunoglobulin fusion proteins whose in vivo half-life is increased in ferrets by a modified ferret IgG Fc region can be useful to test therapeutics in ferrets and ferret models. | 09-17-2015 |
Thomas C. Nesspor, Collegeville, PA US
Patent application number | Description | Published |
---|---|---|
20100249032 | Human EPO Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 09-30-2010 |
Thomas C. Nesspor, Limerick, PA US
Patent application number | Description | Published |
---|---|---|
20090220506 | HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 09-03-2009 |